Long-term Efficacy, Tolerance and Compliance of Panthera D-SAD® Mandibular Advancement Orthosis in Sleep Apnea
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Device: D-SAD
- Registration Number
- NCT05461417
- Lead Sponsor
- Panthera Dental Inc.
- Brief Summary
Obstructive sleep apnea (OSA) is a common, chronic and serious medical condition. Oral appliance therapy (OAT) also called mandibular advancement orthosis (MAO) provides long-term therapy for OSA patients. The Panthera D-SAD® is a computer aided design (CAD)/computer aided manufacturing (CAM), patient-matched, 3D printed, biocompatible nylon OAT. This five-year, observational prospective and multicenter study will assess the effectiveness of the PANTHERA D-SAD® orthosis on reducing the apnea hypopnea index (AHI) and obstructive sleep apnea-hypopnea syndrome (OSAHS) symptoms. Adherence, tolerance, and side effects will be evaluated.
An estimated ten sites composed of a professional dyad, a specialist in sleep disorders, and a practitioner with knowledge of both sleep and the manducatory apparatus will recruit 337 patients. The entry criteria include an AHI between 15 and 30 or higher if the patient meets certain medical and dental criteria, no prior use of OAT, and struggles or refuses continuous positive airway (CPAP) treatment. The professional collaborative nature of the study reflects real-world clinical practice.
Participants will be followed over the course of five years at the following time points. Visits include the following: Specialist in sleep disorders: (1) Inclusion, (2) 3 months, (3) 2 years, (4) 5 years. Specialist in manducatory apparatus (dentist): (1) Inclusion, orthosis set-up and titration, (2) 6 months, (3) 2 and (4) 5 years The efficacy of the Panthera D-SAD® MAO will be assessed by the treatment success rate at five years, defined as a reduction ≥ 50% in the initial AHI, when monitored by nocturnal breathing polygraphy (NP) or polysomnography (PSG). Secondary endpoints will also be obtained at the aforementioned time points for reporting. The results of this study will fulfill regulatory requirements for reimbursement in France.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 337
- Male or female ≥18
- Moderate OSAHS or severe OSAHS and refuse or intolerance to treatment with continuous positive pressure
- Patient who has never worn MAO
- Accepting and able to complete questionnaires in French on the impact of their disease and their quality of life
- Informed and having signed a written consent
- Affiliated to a social security system
- One or more contraindications to wearing a mandibular advancement orthosis
- Central sleep apnea
- Severe OSAHS associated with another sleep pathology
- Serious respiratory disorders other than OSAS
- Severe psychiatric or neurological disorders
- Progressive cancer and/or chronic joint, inflammatory or immunosuppressive disease
- Known allergy to one of the components of the medical device
- Simultaneous participation in another intervention research
- Vulnerable subjects
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description D-SAD group D-SAD Patients equipped with Panthera D-SAD MAO
- Primary Outcome Measures
Name Time Method Efficacy of the MAO Panthera D-SAD® evaluated by the success rate of the treatment at 5 years At 5 years after treatment start Proportion of patients with a reduction in AHI of 50% or more compared to inclusion, measured by polygraphy or somnopolygraphy
- Secondary Outcome Measures
Name Time Method Description of tiredness Inclusion, 3 months, 2 years, 5 years Mean score of Pichot scale at each visit
Description of sleepiness Inclusion, 3 months, 2 years, 5 years Mean score of Epworth scale at each visit
Oxygen Desaturation Index (ODI) evolution 3 months, 2 years, 5 years Difference between ODI at visit and at baseline
Dental tolerance Inclusion, during titration, at 3 and 6 months then at 1, 2, 3, 4, 5 years Number of device adverse reaction (DAR), proportion of patients with at least one DAR, number of incidents and deficiencies
Description of snoring Inclusion, 3 months, 2 years, 5 years Mean score of snoring measured by a Likert scale at each visit
Duration with SpO2<90% Inclusion, 3 months, 2 years, 5 years Duration with SpO2\<90%
Titration description during titration Rod length corresponding to optimal treatment
Description of severity groups Inclusion, 3 months, 2 years, 5 years Proportion of patients with AHI ≤ 5, ≤ 15 and ≤ 30 at visit
Minimal oxygen saturation (SpO2) Inclusion, 3 months, 2 years, 5 years Minimum Spo2 at visit
Observance Inclusion, 3 months, 2 years, 5 year Number of nights equipped for a week, number of hours equipped for a night, percentage of patients equipped ≥4h per night
AHI evolution according to severity Inclusion, 3 months, 2 years, 5 years AHI mean in global and in severity subgroups
Change in AHI 3 months, 2 years, 5 years Difference between AHI at visit and at baseline
Quality of life assessed by Nottingham Health Profile (NHP) questionnaire 3 months, 2 years, 5 years Mean score of Nottingham Health Profile (NHP) at each visit
Satisfaction assessed by a Likert scale 3 months, 2 years, 5 years Mean score of satisfaction measured by a Likert scale at each visit
Trial Locations
- Locations (1)
CHU Angers
🇫🇷Angers, France